Announcement PDF 15th August 2024 ASX RELEASE Investor Webinar Invitation The Calmer Co. International Limited (ASX:CCO) is pleased to invite shareholders and prospective investors to attend an investor webinar on MarketOpen Direct Connect to be held on Tuesday 20th August 2024, 3:30pm AEST/ 1:30am AWST. Chief Executive, Dr Anthony Noble will provide a presentation on the preliminary annual results for FY24 and the key strategic growth pillars for FY25. Shareholders and interested investors can register for the webinar via the link below: https://us02web.zoom.us/webinar/register/WN_OedPk-CISUOnrZkAXGHyxw This announcement has been approved by the board of directors. ends The Calmer Co International Limited 96 Victoria Street West End Queensland 4101 ACN: 169 441 874 For further information Investor & Media Relations Matthew Reede Dominion Communications matt@dominion.partners +61 414 483 054 About The Calmer Co. The Calmer Co. International Limited (ASX:CCO), provides natural solutions to calm nerves, support mind and muscle relaxation and induce sleep. The product range includes drinking powders, teas, shots, concentrates and capsules. Sold under our house of brands: Fiji Kava, Taki Mai and Danodan Hempworks in markets including USA, Australia, China, New Zealand and Fiji. The company also distributes the Leilo kava RTD products in the Fiji Islands. Forward Looking Statements This ASX release includes certain forward-looking statements that are based on information and assumptions known to date and are subject to various risks and uncertainties. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of The Calmer Co. These factors may cause actual results to differ materially from those expressed in the statements contained in this announcement. 2